Bronchoscopy in Lower Respiratory Tract Infection in Respiratory Intensive Care Unit

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-05-31

Study Completion Date

2023-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Evaluate the diagnostic and therapeutic role of fiberoptic bronchoscopy in management of patients with lower respiratory tract infection in Respiratory Intensive Care Unit of Assiut University Hospital

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Role of Toilet Bronchoscopy in RICU

NCT04798118

COPD Asthma Cystic Fibrosis

UNKNOWN NA

Netosis in Determination of Respiratory Infection Severity

NCT04318691

Respiratory Infection

COMPLETED

Fiberoptic Bronchoscopy and Bronchoalveolar Lavage in Critically Ill Ventilated Patients

NCT04502368

Fiberoptic Bronchoscopy (FOB) Bronchoalveolar Lavage (BAL) Respiratory Disease

UNKNOWN

Validation of a Simple Approach to Estimate Alveolar Recruitability in ARDS Patients

NCT02457741

Acute Respiratory Distress Syndrome

COMPLETED

Respiratory Mechanics in Intensive Care Patients

NCT03420417

Intensive Care Ventilator Lung

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Since its introduction in daily medical practice in the late 20th century, fiberoptic bronchoscopy (FOB) has had an increasing role in the everyday life of the pulmonologist. Not only for diagnosis, but also for therapeutic interventions, it has achieved widespread use and is now performed in a diversity of clinical scenarios. For several reasons, from easy performance in trained hands to versatility, diagnostic reliability, and safety, flexible bronchoscopy is now widely accepted and increasingly used in the management of critically ill patients.

A wide range of indications exists for FOB in the intensive care unit (ICU). Most correspond to basic bronchoscopy with exploration, lavage, brushing, and forceps sampling as the primary used techniques. It is recommended that intensive care units account for the facility to perform urgent and timely FOB for a range of therapeutic and diagnostic purposes. Critical care settings demand that respiratory system problems be resolved and clinical decisions be made in a timely manner.

Although one can generally group the indications for bronchoscopy into diagnostic and therapeutic, there are circumstances in which the examination serves both purposes. The main indications for flexible bronchoscopy in the intensive care unit are the visualization of the airways, sampling for diagnostic purposes and management of the artificial airways.

Respiratory infections account for significant morbidity, mortality, and healthcare-related expenditure in patients admitted to the Intensive Care Unit (ICU). Respiratory infections account for 3.5 million deaths worldwide and 79 million loss of disability-adjusted life-years.

The bacteriological profile of pulmonary infections varies within the same country, with time due to differences in the frequency of use of antibiotics, environmental factors, and ventilation in the critically ill patients. Likewise, an expanded variety of emerging pathogens provide challenges for the microbiology laboratory. It has been reported clinical microbiologists in diagnostic laboratories have a critical role to play in the diagnosis and management of lower respiratory tract infection (LRTI) as overtreatment of acute uncomplicated pulmonary infections led to unparalleled levels of multi drug resistance among pathogens. Since the etiological agents of pulmonary infections (LRTI) cannot be determined clinically, microbial investigation is required for both treatment and management of individual case and for epidemiological purposes. Bronchoalveolar lavage (BAL) is an ideal sample that allows the recovery of pathogens cellular and non-cellular components from the epithelial surface of lower respiratory tract. Bronchoalveolar lavage has improved sensitivity and specificity of diagnostic techniques in diagnosis of pulmonary infection. It is increasingly utilized as diagnostic tool though in the past it remained as investigative and research tool as the sputum culture yields diagnosis in fewer than 50% of patients with pulmonary infections. Early diagnosis and proper choice of antimicrobials is crucial for management of these patients. The advent of bronchoscopy and quantitative analysis of BAL have improved sensitivity and specificity in diagnosis of pulmonary infections.

Antibiotics form the main stay of treatment of various respiratory infections which are often initiated empirically based on their previous experiences, hence, leading to the inappropriate use of antibiotics and antimicrobial resistance. Resistance to antibiotics has emerged recently due to misuse of antibiotics and is a threat to health-care system, especially in developing countries where there are no antimicrobial stewardship programs in most ICUs.

Antimicrobial resistance results in increased economic burden on patients due to the higher cost of antibiotics, prolonged ICU stay, and increased mortality. Prescribing appropriate antibiotics for the right duration is very important to prevent drug resistance. Local knowledge regarding the most common organisms and their resistance pattern in various infections will greatly assist clinicians in choosing appropriate initial antibiotic therapy. Hence, it is important to know the antibiotic prescribing pattern and resistance patterns in ICU.

In critically ill patients, mechanical ventilation might cause ventilator-induced lung injury and hospital-acquired pneumonia, both conditions promote atelectasis and stagnant secretions that may worsen oxygenation and delay weaning from ventilator.

Atelectasis may result from numerous causes, for example, from congestion of mucus in the central airways, from increased sputum production, from decreased mucociliary clearance, from decreased cough effectiveness, from increased sputum viscosity, or by a combination of these factors. Treatment of atelectasis in intensive care unit (ICU) patients has been focused on blind airway suctioning, bronchoscopy with or without adjuncts such as nebulization of N-acetylcysteine, and chest physiotherapy. Bronchoscopy is regarded as an attractive method for endobronchial mucus clearing, which possibly results in a more effective airway clearance as it is performed under direct visualization of the airways.

Therefore, removing the sputum is important for patient management, but blind negative pressure aspiration can damage the airway mucosa and leave sputum in place, worsening the patient's condition. Removing sputum under bronchoscopy could allow the precise removal of all sputum while minimizing mucosa damage.

Acute respiratory failure (ARF) has long been a challenge for physicians who perform bronchoscopy for diagnostic or therapeutic purposes. Hypoxaemia is aggravated when implementing bronchoalveolar lavage (BAL) or therapeutic intervention. Many physicians lose their chance to perform bronchoscopy and acquire adequate samples for appropriate treatment. Since undergoing a bronchoscopy can be hazardous to patients with ARF, intubation is preferred and physicians are reluctant to achieve BAL sample. Therefore, bronchoscopic procedures in high-risk patients, especially those with hypoxaemia, have long been a challenge in this field. Few clinical studies have shown the effectiveness of performing bronchoscopy using high flow nasal cannula (HFNC) in ARF for diagnostic purpose.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lower Respiratory Tract Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

fiberoptic bronchoscopy

Will be performed according to British Thoracic Society guidelines 2013.

-Microbiological methods The specimen (tracheal aspirate \& BAL) will be collected under aseptic conditions in a sterile container and immediately sent to the laboratory for microbiological analyses.

Samples will be apply for:

1. Direct smear by Gram stain and ZeihlNelseen stain
2. Samples culturedinBact/alert bottle(BioMérieux, France).
3. Isolation of causative organism from positive cases by:

Subculture on MacConkey , blood , chocolate agar , Sabouroud's agar and Lowenstien Jensen media.
4. Identification of isolated organism and drug sensitivity test by Automated Vitek2 Compact(BioMérieux, France).
5. Multiplex PCR for detection of Respiratory viruses in lower respiratory tract

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult patients \> 18 years old in R.I.C.U who are on mechanical ventilator or high flow nasal cannula oxygen with lower respiratory tract infection or who show atelectasis on CXR in which the standard therapy failed will be included in this study

Exclusion Criteria

* Severely hypoxemic patients under high-FiO2 support and/or high PEEP, if the patient is unable to keep oxygen saturation \>90% with an FiO2 of 0.9-1.0 or a PaO2/FiO2 ratio of \<100, Severe acidosis, Ph\<7,2
* Presence of pneumothorax
* Active bronchospasm.
* Patients with acute coronary problems, such as acute arrhythmia, acute myocardial infarction or ongoing hemodynamic instability, under vasoactive therapy.
* patients with known intracranial hypertension
* patients have coagulation abnormalities, such as thrombocytopenia or elevated prothrombin time

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No